Logo image of ACAD

ACADIA PHARMACEUTICALS INC (ACAD) Stock Fundamental Analysis

NASDAQ:ACAD - Nasdaq - US0042251084 - Common Stock - Currency: USD

22.56  +0.01 (+0.04%)

After market: 22.51 -0.05 (-0.22%)

Fundamental Rating

6

ACAD gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. ACAD has an excellent financial health rating, but there are some minor concerns on its profitability. ACAD is growing strongly while it is still valued neutral. This is a good combination! These ratings could make ACAD a good candidate for growth investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

ACAD had positive earnings in the past year.
In the past year ACAD had a positive cash flow from operations.
ACAD had negative earnings in 4 of the past 5 years.
In multiple years ACAD reported negative operating cash flow during the last 5 years.
ACAD Yearly Net Income VS EBIT VS OCF VS FCFACAD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

The Return On Assets of ACAD (20.23%) is better than 97.49% of its industry peers.
With an excellent Return On Equity value of 29.93%, ACAD belongs to the best of the industry, outperforming 97.67% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 9.30%, ACAD belongs to the top of the industry, outperforming 94.80% of the companies in the same industry.
Industry RankSector Rank
ROA 20.23%
ROE 29.93%
ROIC 9.3%
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
ACAD Yearly ROA, ROE, ROICACAD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

The Profit Margin of ACAD (22.99%) is better than 95.70% of its industry peers.
The Operating Margin of ACAD (8.84%) is better than 93.73% of its industry peers.
ACAD has a Gross Margin of 92.08%. This is amongst the best in the industry. ACAD outperforms 93.37% of its industry peers.
ACAD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 8.84%
PM (TTM) 22.99%
GM 92.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
ACAD Yearly Profit, Operating, Gross MarginsACAD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ACAD is destroying value.
Compared to 1 year ago, ACAD has more shares outstanding
The number of shares outstanding for ACAD has been increased compared to 5 years ago.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACAD Yearly Shares OutstandingACAD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ACAD Yearly Total Debt VS Total AssetsACAD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ACAD has an Altman-Z score of 5.21. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 5.21, ACAD is doing good in the industry, outperforming 77.96% of the companies in the same industry.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.21
ROIC/WACC0.95
WACC9.74%
ACAD Yearly LT Debt VS Equity VS FCFACAD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

ACAD has a Current Ratio of 2.87. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.87, ACAD is doing worse than 66.31% of the companies in the same industry.
ACAD has a Quick Ratio of 2.80. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
ACAD's Quick ratio of 2.80 is on the low side compared to the rest of the industry. ACAD is outperformed by 64.87% of its industry peers.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.8
ACAD Yearly Current Assets VS Current LiabilitesACAD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 5000.00% over the past year.
ACAD shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.39%.
Measured over the past years, ACAD shows a very strong growth in Revenue. The Revenue has been growing by 23.08% on average per year.
EPS 1Y (TTM)5000%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)22.39%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%18.7%

3.2 Future

Based on estimates for the next years, ACAD will show a very strong growth in Earnings Per Share. The EPS will grow by 44.65% on average per year.
The Revenue is expected to grow by 10.99% on average over the next years. This is quite good.
EPS Next Y11.46%
EPS Next 2Y33.01%
EPS Next 3Y49.22%
EPS Next 5Y44.65%
Revenue Next Year9.25%
Revenue Next 2Y10.15%
Revenue Next 3Y11.29%
Revenue Next 5Y10.99%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ACAD Yearly Revenue VS EstimatesACAD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
ACAD Yearly EPS VS EstimatesACAD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

ACAD is valuated quite expensively with a Price/Earnings ratio of 46.04.
Based on the Price/Earnings ratio, ACAD is valued cheaply inside the industry as 92.65% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.50, ACAD is valued quite expensively.
ACAD is valuated quite expensively with a Price/Forward Earnings ratio of 26.57.
ACAD's Price/Forward Earnings ratio is rather cheap when compared to the industry. ACAD is cheaper than 91.22% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ACAD to the average of the S&P500 Index (36.44), we can say ACAD is valued slightly cheaper.
Industry RankSector Rank
PE 46.04
Fwd PE 26.57
ACAD Price Earnings VS Forward Price EarningsACAD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ACAD is valued cheaper than 92.47% of the companies in the same industry.
ACAD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ACAD is cheaper than 91.76% of the companies in the same industry.
Industry RankSector Rank
P/FCF 76.31
EV/EBITDA 38.28
ACAD Per share dataACAD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ACAD does not grow enough to justify the current Price/Earnings ratio.
ACAD has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ACAD's earnings are expected to grow with 49.22% in the coming years.
PEG (NY)4.02
PEG (5Y)N/A
EPS Next 2Y33.01%
EPS Next 3Y49.22%

More info and screens

0

5. Dividend

5.1 Amount

ACAD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACADIA PHARMACEUTICALS INC

NASDAQ:ACAD (7/18/2025, 8:00:00 PM)

After market: 22.51 -0.05 (-0.22%)

22.56

+0.01 (+0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners104.58%
Inst Owner Change0%
Ins Owners0.31%
Ins Owner Change3.85%
Market Cap3.78B
Analysts76.15
Price Target27.54 (22.07%)
Short Float %7.73%
Short Ratio5.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-56.13%
Min EPS beat(2)-109.07%
Max EPS beat(2)-3.19%
EPS beat(4)2
Avg EPS beat(4)-15.12%
Min EPS beat(4)-109.07%
Max EPS beat(4)41.97%
EPS beat(8)5
Avg EPS beat(8)19.9%
EPS beat(12)7
Avg EPS beat(12)13.32%
EPS beat(16)10
Avg EPS beat(16)17.13%
Revenue beat(2)1
Avg Revenue beat(2)-4.13%
Min Revenue beat(2)-8.33%
Max Revenue beat(2)0.08%
Revenue beat(4)2
Avg Revenue beat(4)-2.23%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.66%
Revenue beat(8)5
Avg Revenue beat(8)0.17%
Revenue beat(12)6
Avg Revenue beat(12)-0.72%
Revenue beat(16)7
Avg Revenue beat(16)-1.86%
PT rev (1m)1.04%
PT rev (3m)8.69%
EPS NQ rev (1m)-2.3%
EPS NQ rev (3m)-18.19%
EPS NY rev (1m)-9.94%
EPS NY rev (3m)-19.09%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)0.18%
Valuation
Industry RankSector Rank
PE 46.04
Fwd PE 26.57
P/S 3.79
P/FCF 76.31
P/OCF 25.34
P/B 4.94
P/tB 5.83
EV/EBITDA 38.28
EPS(TTM)0.49
EY2.17%
EPS(NY)0.85
Fwd EY3.76%
FCF(TTM)0.3
FCFY1.31%
OCF(TTM)0.89
OCFY3.95%
SpS5.95
BVpS4.57
TBVpS3.87
PEG (NY)4.02
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 20.23%
ROE 29.93%
ROCE 10.62%
ROIC 9.3%
ROICexc 9.3%
ROICexgc 10.83%
OM 8.84%
PM (TTM) 22.99%
GM 92.08%
FCFM 4.97%
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
F-Score5
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 151.14%
Profit Quality 21.61%
Current Ratio 2.87
Quick Ratio 2.8
Altman-Z 5.21
F-Score5
WACC9.74%
ROIC/WACC0.95
Cap/Depr(3y)241.2%
Cap/Depr(5y)203.04%
Cap/Sales(3y)1.85%
Cap/Sales(5y)1.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5000%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y11.46%
EPS Next 2Y33.01%
EPS Next 3Y49.22%
EPS Next 5Y44.65%
Revenue 1Y (TTM)22.39%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%18.7%
Revenue Next Year9.25%
Revenue Next 2Y10.15%
Revenue Next 3Y11.29%
Revenue Next 5Y10.99%
EBIT growth 1Y1912.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.12%
EBIT Next 3Y44.84%
EBIT Next 5Y49.94%
FCF growth 1Y188.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y367.79%
OCF growth 3YN/A
OCF growth 5YN/A